PODD vs. TFX, GMED, BAX, NVCR, RMD, SWAV, SOLV, PEN, STVN, and GKOS
Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Teleflex (TFX), Globus Medical (GMED), Baxter International (BAX), NovoCure (NVCR), ResMed (RMD), Shockwave Medical (SWAV), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), and Glaukos (GKOS). These companies are all part of the "surgical & medical instruments" industry.
Teleflex (NYSE:TFX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
Teleflex has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Insulet has a net margin of 13.14% compared to Insulet's net margin of 9.82%. Teleflex's return on equity of 34.06% beat Insulet's return on equity.
In the previous week, Insulet had 9 more articles in the media than Teleflex. MarketBeat recorded 24 mentions for Insulet and 15 mentions for Teleflex. Insulet's average media sentiment score of 0.96 beat Teleflex's score of 0.20 indicating that Teleflex is being referred to more favorably in the media.
Teleflex has higher revenue and earnings than Insulet. Teleflex is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Insulet received 194 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 66.05% of users gave Insulet an outperform vote while only 59.54% of users gave Teleflex an outperform vote.
95.6% of Teleflex shares are held by institutional investors. 1.4% of Teleflex shares are held by insiders. Comparatively, 0.5% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Teleflex presently has a consensus target price of $261.75, indicating a potential upside of 20.27%. Insulet has a consensus target price of $239.44, indicating a potential upside of 27.86%. Given Teleflex's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than Teleflex.
Summary
Insulet beats Teleflex on 11 of the 18 factors compared between the two stocks.
Get Insulet News Delivered to You Automatically
Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
